Two years and $78M later, Amgen washes its hands of Advaxis' I/O drug — and shares plummet
Advaxis has taken its investors on a bit of a roller coaster ride this year.
The FDA slapped a clinical hold on a combo study …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
